



AN API & CDMO COMPANY

GLOCHEM INDUSTRIES



Excellence in Every Molecule. Driven by Science. Designed for
the Future.

Company Overview · All Pages
Generated: 21 August 2026

TABLE OF CONTENTS

1	Home	Philosophy, Group of Companies, Manufacturing Overview, Global Presence
2	About Us	Company Story, Leadership Team, Certifications
3	Our Products	API Commercial, Products Under Development, Intermediates & KSMs, Speciality Chemicals
4	Research & Facilities	World Class R&D, API R&D, CDMO R&D, Core Chemistry, IP Management
5	Manufacturing	API/CRAMS Capability, Group of Companies, Capabilities Detail, Equipment Tables
6	Sustainability	Approach, Climate Action, Safety Excellence, Governance Framework, Impact
7	ESG	ESG Profile, Recognitions, Low Carbon Model, OHS Actions, Milestones
8	Get In Touch	Communication Channels, Office Network

Glochem Industries is an API & CDMO company with dedicated manufacturing sites for CDMO, committed to excellence in every molecule — driven by science and designed for the future.

OUR PHILOSOPHY: FIT FOR FUTURE

Safety First, Quality Always, Productivity Daily

Glochem operates at the intersection of pharmaceutical APIs, CDMO solutions, and specialty chemicals — pooling and creating efficiencies across sectors. The company is a **Proud Member of the UN Global Compact (UNGC)**.

GROUP OF COMPANIES

Specialized subsidiaries driving innovation across pharmaceutical sectors:

CHIERON

High quality generic API (with key markets: US, Europe, Japan, Korea & Brazil). End-to-end CDMO Solutions for complex molecules and KSMs, from development to commercial marketing. High Purity material for Semi-Conductors, OLED & Specialty Chemicals.
chieron.com

MAKSONS

Dedicated CDMO units for Intermediates, Specialty Chemicals & OLED. Advanced specialty chemicals for high-performance applications, driven by precision, customization, and scalable manufacturing.
maksons.com

MANUFACTURING CAPABILITIES (SUMMARY)

Particulars	Chieron	Glochem	Maksons
Total Reactors	41	46	13
Dryers	10	16	02
Reactors – SSR	38	38	10
Reactors – GLR	21	8	03
Size Reduction Equipment	07	12	01

GLOBAL PRESENCE NETWORK

Glochem maintains a strong sales presence across international markets including US, Europe, Japan, Korea, Brazil, and emerging markets.

OUR OFFICE NETWORK

HYDERABAD (CORPORATE)

3rd Floor, NCC Building, Vital Rao Nagar Colony,
Hyderabad 500 081

AHMEDABAD

Plot No. C-10, Akshar Industrial Park, Opp. Zydus Life
Sciences, Changodar - 382213, Gujarat

MUMBAI

20th Floor, Tower 2, Unit No. 2001, One International
Center, Senapati Bapat Marg, Mumbai - 400 013

BANGALORE

91 Springboard, Bannerghatta Rd, Dollars Colony,
Phase 4, J. P. Nagar, Bengaluru 560076

Excellence in Every Molecule. Driven by Science. Designed for the Future.

OUR STORY

2026

- Acquired Maksons Fine Chemicals

2025

- Transition from Venkata Narayana Active Ingredients Pvt Ltd (VNAI) – Chieron Active Ingredients Pvt Ltd (CAI)
- Successfully completed PMDA audit in May 2025
- Inception of a new R&D facility in Ahmedabad
- Acquired Glochem Industries Pvt. Ltd.
- Successful WHO GMP audit in July 2025 and USFDA in 2024
- Chieron – Ecovadis Gold Certification
- Glochem – Ecovadis Bronze Certification

2024

- CEP approval received for 2 APIs
- ECOVADIS certification achieved
- Awarded the Golden Peacock for sustainability
- Applied for PSCI membership
- Achieved B rating in CDP

2023

- China approval – Received 'A' status for 4 APIs
- First filing in CADIFA, Brazil – Olmesartan

2020

- State-of-the-art production block-2 inaugurated

2017–2019

- USFDA site approval I & II

2016

- Achieved zero liquid discharge (ZLD) milestone

2015

- EDQM approval obtained

2011

- KFDA approval obtained

2010

- WHO GMP & ISO-9001 certified

2008–2009

- First Drug Master Files (DMFs) filed globally

2007

- Start of commercial manufacturing operations

CORE VALUES

TRUSTED

by global regulators &
customers

INNOVATIVE

portfolio expansion

COMMITMENT

to safety, quality &
excellence

WORKUP & ISOLATION

Advanced equipment for downstream operations like Sparkler filter, ANF & ANFD etc.

High-vacuum distillation and VTD systems

CGMP-compliant purification for heat-sensitive and viscous intermediates

MANAGEMENT TEAM

Visionary leadership driving scientific excellence and global operations

Mr. Chandra Kumar Verma

MD & Chief Executive Officer

Visionary business leader with over two decades of experience across global APIs, intermediates, and formulations. Holds a B.E. in Chemical Engineering and a PGDM in Marketing & Operations. Successfully scaled businesses to revenues exceeding USD 200 million. Led multiple M&A transactions; launched over 300 APIs and 50 FDFs across regulated and emerging markets.

Mr. Bodhisatwa Ray

Chief Finance Officer

Seasoned finance leader with over 20 years of global experience. Chartered Accountant and alumnus of IIM Ahmedabad. Spent over a decade at Pfizer leading finance, taxation, treasury, and M&A. Has held leadership roles at Dr. Reddy's Laboratories and HSBC. Focuses on financial governance, transparency, and value creation.

Mr. Naga Seshiah Kalki

Chief Operating Officer

Operations leader with 35+ years of experience across sterile and non-sterile APIs and Injectable dosage forms. Proven track record in leading large-scale manufacturing operations, delivering greenfield and brownfield projects, and successfully navigating USFDA and international regulatory audits. Worked with Lupin, Orchid Pharma, Ranbaxy, Hospira, Biocon. Graduate in Pharmacy with a PGDIM.

Dr. Swarup Datta

Vice President & Head – R&D (CDMO)

Pharmaceutical R&D leader with two decades of experience. Held leadership roles at Piramal Pharma, Aragen Life Sciences, Glenmark Life Sciences, Syngene International, and Daiichi Sankyo India Pharma. PhD in Organic Chemistry from National Tsing Hua University, Taiwan; postdoctoral experience from University of Saarland, Germany, and University of Oxford, UK.

Dr. Kirti Prakash Jain

Head – R&D

R&D executive with over 24 years of distinguished leadership in Active Pharmaceutical Ingredient (API) research, process development, and commercial manufacturing. Held pivotal R&D leadership roles at Sun Pharma, Ipca Laboratories, Hikal, Ami Life Sciences, Cadila Pharmaceuticals, and Ranbaxy Laboratories. Leads the organization's R&D center in Ahmedabad, driving end-to-end API strategy, flow chemistry, process intensification, and green technologies. Holds M.Sc. and Ph.D. in Chemistry with credit for over 25 patented technologies.

Mr. T. G. Vinod

Chief Supply Chain Officer

Seasoned supply chain leader with over 25 years of pharmaceutical industry experience. Held leadership roles at Dr. Reddy's Laboratories and ZCL Chemicals. Managed procurement spends exceeding USD 100 million. Built resilient supplier networks across India and China.

Venkat "Srini" Srinivas

Chief Information Officer

Transformational technology leader with over 25 years of global experience driving digital innovation across the pharmaceutical and life sciences industries. Prior senior executive roles at Apotex and Cohance Lifesciences. Holds a B.E. in Computer Science and an MBA with executive education from NMIMS.


Niraj Agrawal

Chief Human Resources Officer

Strategic HR leader with over three decades of experience shaping organizations. Led HR agendas at Dr. Reddy's Laboratories, Wockhardt, HVAL (Tata Enterprise), Essel Mining (Aditya Birla Group), and Deepak Fertilisers. Holds a PG Diploma in Personnel Management from XISS, Ranchi.

CERTIFICATIONS

Accredited by leading international quality, environmental, and safety organizations:



FIT FOR FUTURE through Sustainable Excellence

API COMMERCIAL (26 PRODUCTS)

S.No	API	USDMF	CEP	JDMF	KDMF	CADIFA	CDMF	Therapeutic Use
1	AIPAU	--	--	√	√	--	--	Analgesic
2	Benfotiamine	--	--	--	--	--	--	Vitamin Supplement
3	Dapagliflozin Propanediol	√	√	--	--	--	--	Anti Diabetic
4	Lacosamide	√	√	√	√	√	A Status	Anti Convulsant
5	Levetiracetam	√	√	√	√	√	A Status	Anti Convulsant
6	Linagliptin	√	EDMF	--	--	√	√	Anti Diabetic
7	Loxoprofen Acid / Sodium	--	--	--	--	--	--	Anti Inflammation
8	Olmesartan Medoxomil	√	√	√	√	√	√	Anti Hypertensive
9	Oseltamavir Phosphate	--	--	--	--	--	*	Anti viral
10	Quetiapine Fumarate	--	--	--	--	--	--	Anti Psychotic
11	Risperidone	√	√	--	√	√	√	Anti Psychotic
12	Rivaroxaban	√	*	--	--	--	--	Anticoagulant
13	Sitagliptin Phosphate (Chemical)	√	*	--	--	--	--	Anti Diabetic
14	Sitagliptin Phosphate (Enzymatic)	√	*	--	--	--	--	Anti Diabetic
15	Tetracaine Base/ HCL	√	√	--	--	√	A Status	Anaesthetic
16	Vildagliptin	√	--	--	--	--	--	Anti Diabetic

S.No	API	USDMF	CEP	JDMF	KDMF	CADIFA	CDMF	Therapeutic Use
17	Warfarin S Amorphous	√	√	--	--	--	*	Coagulant
18	Warfarin S Clathrate	√	√	--	--	--	√	Anti Coagulant
19	Amlodipine Besylate	√	√	√	√	√	√	Anti Hypertensive
20	S(-) Amlodipine Besylate	√	--	--	√	√	--	Anti Hypertensive
21	Amlodipine Maleate	--	--	--	--	Status	--	Anti Hypertensive
22	Cetirizine Dihydrochloride	√	--	--	√	A Status	√	Anti Histaminic
23	Levocetirizine Dihydrochloride	√	√	√	√	√	√	Anti Histamines
24	Hydroxyzine Hydrochloride	√	√	--	--	√	√	Anti Histaminic
25	Raloxifene Hydrochloride	√	√	--	--	--	--	Anti Osteoporotic
26	Telmisartan	√	√	--	--	--	--	Anti Hypertensive

PRODUCTS UNDER DEVELOPMENT

Product 1	Product 2	Product 3
Azilsartan Medoxomil Potassium	Eprazinone dihydrochloride	Ezetimibe
Methylphenidate	Nebivolol hydrochloride	Pelubiprofen
Tegoprazan	Vonoprazan Fumarate	Zonisamide
Bilastine	Famotidine	Lercanidipine

API – UNDER EVALUATION

Product Name		
Risdiplam	Tegoprazan	Pelubiprofen
Acoramidis	Isavuconazole	Fosravuconazole
Fluvoxamine Maleate	Fenfluramine	Vilanterol
Retagliptin	Elafibranor	Anagliptin

Product Name		
Nafamostat	Sotagliflozin	Lumateperone
Levothyroxine Sodium	Tolvaptan	Rebamipide
Letermovir	Finerenone	Roxadustat
Mavacamten	Eprazinone	Ipragliflozin
Opicapone	Dorzagliatin	

INTERMEDIATES & KSMS (35 ITEMS)

S.No	Product / Intermediate	CAS No.	End Product
1	Amlodipine Phthalimido / Base	88150-62-3, 88150-42-9	Amlodipine
2	4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one	91526-18-0	Azilsartan medoxomil
3	Methyl 1-[(2'-Cyano-[1,1'-biphenyl]-4-yl)methyl]-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate	139481-44-0	Azilsartan medoxomil
4	Methyl 2-ethoxy-1-((2'-(N-hydroxycarbamimidoyl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate	147403-65-4	Azilsartan medoxomil
5	Methyl 2-Ethoxy-1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]methyl]benzimidazole-7-carboxylate	147403-52-9	Azilsartan medoxomil
6	Azilsartan (2-Ethoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid)	147403-03-0	Azilsartan medoxomil
7	8-bromo-7-(but-2-ynyl)-3-methyl-1H-purine-2,6(3H,7H)-dione (LG-1)	666816-98-4	Linagliptin
8	2-(4-(bromomethyl)phenyl) propanoic acid (BPP)	111128-12-2	Loxoprofen
9	Methyl Cyclopentanone-2-carboxylate (MCP)	10472-24-9	Loxoprofen
10	2-Phenyl-2-(Pyridine-2-yl)acetamide (PPA)	7251-52-7	Methylphenidate
11	Ritinalic Acid**	19395-41-6	Methylphenidate
12	2-Phenyl-2-(Piperidine-2-yl) acetamide (Mixture of Diastereomers)	19395-39-2	Methylphenidate
13	6-Fluoro-3,4-Dihydro-2H-benzopyran-2-Carboxylic acid	99199-60-7	Nebivolol HCl

S.No	Product / Intermediate	CAS No.	End Product
14	(±)-[R*(R*)]-6-Fluoro-3,4-Dihydro-2-Oxiranyl-2H-1-Benzopyran	876514-31-7	Nebivolol HCl
15	(±)-[1S*(R*)]-6-Fluoro-3,4-Dihydro-2-Oxiranyl-2H-1-Benzopyran	793669-26-8	Nebivolol HCl
16	rac N-Benzyl Nebivolol // BENL	929706-85-4	Nebivolol HCl
17	Trityl Olmesartan Medoxomil	144690-92-6	Olmesartan
18	Ethyl 4-(1-hydroxyl-1-methylethyl)-2-propyl-imidazole-5-carboxylate	144689-93-0	Olmesartan
19	(1S,5R,6S)-Ethyl 5-(pentan-3-yloxy)-7-oxa bicyclo[4.1.0]hept-3-ene-3-carboxylate	204254-96-6	Oseltamivir
20	4-CHLOROMETHYL-5-METHYL-1,3-DIOXOL-2-ONE (DMCO Cl)	80841-78-7	Olmesartan
21	Ethyl (3R,4R,5S)-4-(N-tert-butylacetamido)-5-(diallylamino)-3-(pentan-3-yloxy)-cyclohex-1-enecarboxylate hydrochloride	651324-08-2	Oseltamivir
22	Dibenzo[b,f] thiazepine-11(10H)-one	3159-07-7	Quetiapine Fumarate
23	1-[2-(2-Hydroxyethoxy)ethyl]Piperazine	13349-82-1	Quetiapine Fumarate
24	(R)-5-Chloro-N-(2-hydroxy-3-((4-(3-oxo morpholino)phenyl)amino)propyl)thiophene-2-carboxamide	721401-53-2	Rivaroxaban
25	1-(3-(Trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butane-1,3-dione	764667-65-4	Sitagliptin
26	2-(2,4,5-trifluorophenyl)acetic acid	209995-38-0	Sitagliptin
27	3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride	762240-92-6	Sitagliptin
28	4-[[[(4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-yl]oxy]-N,N,2-trimethyl-1-[(4-methylphenyl)sulfonyl]-1H-benzimidazole-6-carboxamide]	942485-42-9	Tegoprazan
29	(4S)-5,7-difluoro-3,4-dihydro-2H-1-benzopyran-4-ol	942195-91-7	Tegoprazan
30	4-hydroxy-N,N,2-trimethyl-1-[(4-methylphenyl)sulfonyl]-1H-benzimidazole-6-carboxamide	942195-86-0	Tegoprazan
31	N,N,2-trimethyl-1-[(4-methylphenyl)sulfonyl]-4-(phenylmethoxy)-1H-benzimidazole-6-carboxamide	942195-85-9	Tegoprazan

S.No	Product / Intermediate	CAS No.	End Product
32	5-(2-Fluorophenyl)-1H-pyrrole-3-carboxaldehyde	881674-56-2	Vonoprazan Fumarate
33	5-(2-Fluorophenyl)-1-[(pyridin-3-yl)sulfonyl]-1H-pyrrole-3-carboxaldehyde	881677-11-8	Vonoprazan Fumarate
34	Ethyl 5-(2-fluorophenyl)-1H-pyrrole-3-carboxylate	881674-06-2	Vonoprazan Fumarate
35	(S)-2-Methylpyrrolidine-2-carboxylic acid	1508261-86-6	Daridorexant Hydrochloride

SPECIALITY CHEMICALS – OLED, SEMICONDUCTOR & CONTRAST MEDIA (25 ITEMS)

S.No	Chemical Name	CAS No.	End Use
1	Iohexol	66108-95-0	Contrast Media
2	4-Chloro-2-iodoaniline	63069-48-7	Contrast Media
3	5-Nitro Isophthalic acid	618-88-2	Contrast Media
4	Iopamidol	60166-93-0	Contrast Media
5	5-Iodo-2-methylbenzoic acid	54811-38-0	Contrast Media
6	1,4,7,10-Tetraazacyclo dodecane	294-90-6	Contrast Media
7	10-(2-Hydroxypropyl)-1,4,7,10-tetraaza cyclododecane-1,4,7-triacetic acid	120041-08-9	Contrast Media
8	5-Amino-N,N'-bis(2,3-dihydroxypropyl) isophthalamide Hydrochloride	203515-86-0	Iohexol / Contrast Media
9	Dimethyl-5-Nitroisophthalate	13290-96-5	Iohexol / Contrast media
10	5-Amino-2,4,6-Triiodoisophthaloyl Dichloride	37441-29-5	Iohexol / Contrast media
11	5-Amino-2,4,6-Triiodoisophthalic Acid	35453-19-1	Iohexol / Contrast media
12	N-(1-Methylpropyl)-4-[(1-methylpropyl)imino]-2-penten-2-amine	917952-30-8	Semiconductor
13	1,1'-methylene bis (N,N,N,1-tetramethyl silanamine)	86053-30-7	Semiconductor
14	2,2,4-Trimethyl-2,4-Disilapentane	1189-75-9	Semiconductor

S.No	Chemical Name	CAS No.	End Use
15	1-(1-Methylethyl)cyclohexyl 2-methyl-2-propenoate (IPCHMA)	811440-77-4	Semiconductor
16	2-methyl-2-[(hexahydro-2-oxo-3,5-methano-2H-cyclopenta[b]furan-6-yl)oxy]-2-oxoethyl ester, 2-Propenoic acid (ACNLM)	347886-81-1	Semiconductor
17	2-Ethyl-2-adamantyl methacrylate (EAdMA)	209982-56-9	Semiconductor
18	2-Methylacrylic Acid 2-Oxotetrahydrofuran-3-yl Ester	195000-66-9	Semiconductor
19	1-Methyl-1-cyclopentyl Methacrylate (McPMA)	178889-45-7	Semiconductor
20	2-Methyl-2-adamantyl methacrylate (MAdMA)	177080-67-0	Semiconductor
21	3-Hydroxy-1-methacryloyl oxyadamantane (HMA)	115372-36-6	Semiconductor
22	1-(1-methylethyl)cyclopentyl 2-methyl-2-propenoate (IPCPMA)	1149760-04-2	Semiconductor
23	2-Iodobenzoic acid	88-67-5	Specialty Chemicals
24	Diiodomethane	75-11-6	Specialty Chemicals
25	1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide Hydrochloride (EDC-HCl)	25952-53-8	Specialty Chemicals

Innovation Through Integration — Building R&D Capabilities FIT FOR FUTURE

WORLD CLASS R&D CAPABILITIES

Our R&D department leverages scientific expertise and scalable design to drive IP-focused innovation. Through rigorous regulatory standards and collaborative engineering, we provide the global market with high-quality, cost-efficient APIs.

- Scientific, diversified & technical expert team
- Ability to design robust, reproducible, and scalable synthetic routes
- Innovation & Intellectual Property (IP) Creation
- Proven ability to move from lab to kilo lab to pilot plant to commercial scale efficiently
- Ensuring technology transfer packages are complete, reproducible, and compliant

FACILITY

1 R&D facility & 3 Process & Development facilities —
30,000 sq.ft. built-up area

TEAM

100+ Scientific team along
with 20+ PhDs (with
associated partners)

LABS

5 synthesis labs with walk-in
fume hoods & 4 analytical
labs with sophisticated
instruments

API RESEARCH & DEVELOPMENT: WHERE SCIENCE MEETS STRATEGY

- **Advanced Synthetic Design:** Expertly crafting complex molecules and novel synthetic pathways to drive the next generation of APIs.
- **Process Optimization:** Enhancing yields and purity profiles through rigorous chemical engineering and innovative methodology.
- **Analytical Mastery:** Comprehensive characterization and impurity profiling to meet the highest global pharmacopeial standards.
- **IP-Driven Innovation:** A strategic focus on creating and protecting intellectual property to give our partners a competitive market edge.

CDMO R&D (DEVELOPMENT & MANUFACTURING): SEAMLESS SCALE-UP COMMERCIALIZATION

- **Scalable Process Design:** Developing robust chemical processes engineered for reproducible, large-scale commercial manufacturing.
- **Rapid Tech Transfer:** Minimizing time-to-market through streamlined, "right-first time" technology transfer.

- **Regulatory Compliance:** Expert navigation of global regulatory landscapes, ensuring every process is validated and audit-ready.
- **Agile Ecosystem:** In-house infrastructure provides flexibility to pivot between kilo-lab batches and full-scale production campaigns.

CORE CHEMISTRY ACTIVITIES

Complex Heterocyclic And Chiral Chemistry

Hydrogenation And High-Pressure Reactions

Cross-Coupling (Suzuki-Miyaura, Heck Reaction, Buchwald-Hartwig, Sonogashira, Negishi etc.)
And Organometallic Chemistry (Grignard Reaction)

Halogenation, Nitration, Phosgenation & Phosphorylation

Cyanation Process

Carbohydrate Chemistry

INTELLECTUAL PROPERTY MANAGEMENT

ROLES

- Innovation support
- Infringement Screening
- IP-Validation
- FTO-Analysis
- Patent drafting
- Patent Filing
- IP-Alerts

TOOLS / DATABASES

- CAS Scifinder
- United States Patent & Trademark Office
- European Patent Office
- WIPO
- Scopus
- PubMed

TALENT POOL

- Registered Indian Patent Agent with Organic Chemistry PGs & Ph.Ds.
- Experts in data mining in literature databases and interpretation of techno-legal documents
- 15+ Years of Experienced Resources

Sacred Science of Production — Manufacturing with Precision & Purpose

API / CRAMS CAPABILITY – PROVEN IN 20+ APIS & STILL DEVELOPING

Glochem is on a growth trajectory, with plans to introduce 4–7 new API molecules annually, along with new specialty chemicals, while also exploring opportunities in New Chemical Entities (NCE) with originators.

Approximately **80,000 sq. meters** of land is available, and dedicated blocks for CMO activities can be built under a partnership module. Backward integration leads to cost competitiveness, supply reliability, and quality control.

GROUP OF COMPANIES

CHIERON

Complex Generics & Drug Delivery Innovation
DMFs filed: **13** | Under filing (FY 25–26): **6**
CEPs filed: **5** | Under filing (FY 25–26): **7**

MAKSONS

Dedicated CDMO unit for specialty chemicals and OLED
A CDMO and dedicated CRAMS site driven by precision, customization, and scalable manufacturing.

MANUFACTURING CAPABILITIES DETAIL

CHIERON

- **Campus:** 90,000 m² with 80,000 m² expansion-ready
- **Capacity:** 360 KL installed; 200 KL under production
- **Blocks:** 2 independent production blocks (PB-1A & PB-2)
- **Clean rooms:** 6 ISO-8 certified clean rooms
- **Reactors:** 28 SS & GL reactors
- **Downstream:** 7 centrifuges, 10 filters
- **Drying:** 10 dryers, 7 size-reduction units
- **Sustainability:** 15 KL solvent recovery; 100 KL ETP

GLOCHEM INDIA

- **Campus:** 15,135 m² operational
- **Capacity:** 96 KL installed (~50 KL under finalization)
- **Blocks:** 5 independent (PB-1, 2, 4, 5, 6)
- **Clean rooms:** 3 ISO-8 certified
- **Reactors:** 46 reactors, diverse configurations
- **Downstream:** 16 centrifuges, 16 filtration
- **Drying:** 15 dryers, 12 size-reduction
- **Sustainability:** 10 KL SRP; 75 KL ETP

MAKSONS

- **Campus:** 10,300 m² operational
- **Capacity:** 20.13 KL installed
- **Blocks:** 1 independent block (PB-1); new block designed for 120 KL
- **Reactors:** 13 reactors (hazardous chemistry capable)
- **Downstream:** 4 centrifuges, 2 filtration
- **Drying:** 1 VBD & 1 RCVD, 1 micropulverizer
- **Sustainability:** In-process solvent recovery; 13 KL ETP

PARTICULARS

Particulars	Chieron	Glochem India	Maksons
Total site area	169,400 m ² *	15,135 m ²	10,300 m ²
Total capacity	350 KL	56 KL	20.13 KL
Block details	2 blocks (PB1 & PB2)	5 blocks (PB1,2,4,5,6)	1 block (PB-1)
SRP equipment capacity	15 KL	10 KL	–
ETP capacity	100 KL	75 KL	13 KL
No. of clean rooms	6 (ISO-8 certified)	3 (ISO-8 certified)	–

* An additional 50,000 m² is available for setting up new production blocks.

EQUIPMENT DETAILS

Equipment	Chieron	Glochem India	Maksons
Total reactors	41	46	13
Dryers	10	16	02
— SSR (Stainless Steel)	38	38	10
— GLR (Glass Lined)	21	8	03
Size reduction equipment	07	12	01

6 SUSTAINABILITY

FIT FOR FUTURE through Sustainable Excellence

OUR APPROACH TO SUSTAINABILITY

At Glochem, sustainability is not a standalone initiative — it is the foundation of how we operate, innovate, and grow. We integrate sustainable practices into every stage of our business, from responsible sourcing and green chemistry to employee well-being and community development.

Our vision is to create long-term value for our stakeholders while safeguarding the environment and communities in which we operate. We believe that sustainable growth stems from ethical decision-making, efficient resource use, and a commitment to health, safety, and transparency.

"We are committed to manufacturing excellence that protects the planet and empowers people."

SUSTAINABILITY PILLARS

CLIMATE ACTION LEADERSHIP Comprehensive decarbonization strategy aligned with Paris Agreement's 1.5°C scenario. Near-term target by 2035 and Net Zero commitment by 2050, validated by Science Based Targets initiative (SBTi).	GLOBAL SAFETY EXCELLENCE ISO 45001 certified sites with zero fatal accidents record. Continuous safety awareness programs and behavioral safety training across all manufacturing locations.
PROUD MEMBER – BRITISH SAFETY COUNCIL Recognized with the prestigious International Safety Award (Merit 2026) for demonstrating exemplary commitment to health, safety, and workplace well-being standards.	INDUSTRY COLLABORATION Active participation in the Pharmaceutical Supply Chain Initiative (PSCI), adopting sectoral sustainability programs to drive industry-wide environmental and social progress.

SUSTAINABILITY GOVERNANCE FRAMEWORK

At Glochem, sustainability is a shared responsibility led from the top and practiced across every function. Our governance structure ensures that environmental, social, and ethical considerations are integrated into our business strategy, operations, and decision-making processes.

Sustainability oversight begins with the Board of Directors, which reviews sustainability performance and policy updates periodically. The Managing Director provides strategic direction, while the EHS & Sustainability Committee drives implementation across sites and monitors progress against company-wide targets.

"Leadership accountability is at the heart of our sustainability journey."

OUR SUSTAINABILITY IMPACT

20,000 KL

Water reused in FY-25

15.06%

Reduction in Scope 1 emissions

2,812,930

KWh

Renewable energy
consumption

OUR APPROACH FOR LOW CARBON BUSINESS MODEL

INTERNAL INITIATIVES

- Rooftop Solar
- Energy Efficiency Projects
- Energy Management System (EnMS)
- Product Carbon Footprint & Emission Hotspot Identification

EXTERNAL INITIATIVES

- Renewable Energy Access
- Supply Chain GHG Reduction

ESG – ENVIRONMENTAL, SOCIAL & GOVERNANCE

FIT FOR FUTURE through Sustainable Excellence

ESG PROFILE

Your trusted API & CDMO partner for complex chemistry, reliable scale-up, and sustainable growth

EcoVadis Gold & Silver Rated Sites

CDP B Rating (2025) With Zero Liquid Discharge Operations

2 MW Solar Power Utilization

ISO 9001, ISO 14001, OHSAS 18001 Certified

Recipient Of The Golden Peacock Award For EHS Excellence

IOD EVENT: FIRST LAUNCH OF SUSTAINABILITY REPORTS OF GLOCHEM

Glochem marked a significant milestone by launching its inaugural Sustainability Report at the IOD (Institute of Directors) event, reinforcing its commitment to transparent environmental and social governance.

RECOGNITIONS



ecovadis

CDP



GRI



PSCI

Ecovadis

CDP

Science Based Targets

GRI

British Safety Council

UN Global Compact

OUR APPROACH FOR LOW CARBON BUSINESS MODEL

INTERNAL

Solar rooftop, energy efficiency projects, energy management system and product carbon footprint to understand hot spots

EXTERNAL (ACCESS)

Access To Renewable Energy

EXTERNAL (SUPPLY CHAIN)

Supply Chain GHG Reductions

KEY ACTIONS TO ENHANCE OHS CULTURE & SAFETY PERFORMANCE

Management Walk Through Once/Month

Implement SBO App For Safety Reporting Culture & Sense Of Employee Involvement

Safety Part Of Performance Management

BBS Training

Bonus/Incentive Linked With Plant Safety Performance

Endorsement Of National & International Safety Initiatives Like British Safety Council

Safety Awards (Internal – Best Department)

CERTIFICATIONS

We maintain compliance with multiple international standards to continuously improve our processes, minimize risks, and reduce environmental impact. Each certification represents an independent assurance of Chieron's robust governance and sustainability practices.

OUR UPCOMING MILESTONES

Targeting EcoVadis Platinum Award (2026–27)

Participating In ICC, Golden Peacock, And CII Awards

Awarded British Safety Council International Safety Award

Pursuing Green Lab Certification For R&D & Process Labs

Implementing DuPont Engagement Program To Enhance Safety & Operational Excellence

Connect with our Global Business, CDMO Partnerships, and Regulatory Teams

COMMUNICATION CHANNELS

We welcome inquiries regarding commercial API supply, custom synthesis, scale-up, and regulatory filings.

 EMAIL – SALES

sales@glochem.com

 EMAIL – MARKETING

marketing@glochemindia.com

 EMAIL – SUPPLY CHAIN

purchase@glochemindia.com

 EMAIL – HUMAN RESOURCES

careers@glochemindia.com

 PHONE SUPPORT

+91-40-44665065 | Mon – Fri: 9:30 AM – 6:30 PM IST

 CORPORATE HEADQUARTERS

3rd Floor, NCC Building, Durgam Cheruvu Road, Hi Tech City, Madhapur, Hyderabad, Telangana, India

OUR OFFICE NETWORK

Strategically positioned across India's leading pharmaceutical hubs

HYDERABAD (CORPORATE OFFICE)

3rd Floor, NCC Building, Durgam Cheruvu Road, Hi Tech City, Madhapur, Hyderabad, Telangana, India

HYDERABAD (PLANT IDA JEEDIMETLA)

Plot No. 34/B, 34/C, 35, Phase-I, IDA, Jeedimetla, Hyderabad, Telangana - 500 055, India

MUMBAI OFFICE

114, 1st Floor, Neo Corporate Plaza, Kanchpada, Ramchandra Lane Extn., Malad (West), Mumbai - 400 064, India

BANGALORE OFFICE

3rd Floor, SLN arcade, 7th main, 80ft road, 1st block, HRBR layout, Kalyan Nagar, Bangalore - 560 043, India

AHMEDABAD R&D FACILITY

Westgate Business Bay, B Block, 14th Floor, Corporate
Road, Makarba, Ahmedabad - 380 051, Gujarat, India

Glochem Industries · An API & CDMO Company

Safety First · Quality Always · Productivity Daily